

Emergence of KPC-producing *Klebsiella pneumoniae* in Uruguay: infection control and molecular characterization

C. Marquez¹, A. Ingold², N. Echeverría², A. Acevedo², R. Vignoli³, V. García-Fulgueiras³, J. Viroga⁴, O. Gonzalez⁴, V. Odizzio⁵, K. Etulain⁵, E. Nuñez⁶, H. Albornoz⁷, G. Borthagaray⁸ and A. Galiana⁹

1) Cátedra de Microbiología, Instituto de Química Biológica, Facultad de Ciencias y de Química-UdelaR, 2) Facultad de Química-UdelaR, Cátedra de Microbiología, UdelaR, 3) Dpto Bacteriología y Virología, Instituto de Higiene/Facultad de Medicina-UdelaR, Montevideo, 4) Laboratorio Gram/Microbiología, Sanatorio SemmMautone, 5) Comité de Infecciones, Sanatorio SemmMautone, Maldonado, Uruguay, 6) Unidad de Cuidados Intensivos, Sanatorio SemmMautone, 7) Unidad de Cuidados Intensivos, Hospital Maciel, Montevideo, Uruguay, 8) Facultad de Química-UdelaR, Bioquímica Clínica and 9) Dpto Microbiología, Hospital Maciel, UDYCI, Montevideo, Uruguay

Abstract

We describe the first outbreak of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* (KPC-KP), the infection control measures adopted and the shift in resistance patterns of isolates during antibiotic treatment. The ST258 KPC-KP strain exhibited a multiresistant antibiotic phenotype including co-resistance to gentamycin, colistin and tigecycline intermediate susceptibility. Isolates before and after treatment had different behaviour concerning their antibiotic susceptibility and the population analysis profile study. A progressive increase in the aminoglycosides (acquiring ampicillin resistance) and β -lactam MICs, and a decreased susceptibility to fosfomycin was observed throughout the administration of combined antimicrobial regimens including meropenem. A high meropenem resistance KPC-KP homogeneous population (MIC 256 Jg/mL), could arise from the meropenem heterogeneous low-level resistance KPC-KP population (MIC 8 Jg/mL), by the selective pressure of the prolonged meropenem therapy. The *kpc* gene was inserted in a Tn4401 isoform a, and no transconjugants were detected. The core measures adopted were successful to prevent evolution towards resistance dissemination.

Keywords: Antibiotic resistance, infection control, KPC

Original Submission: 19 September 2013; **Revised Submission:** 12 January 2014; **Accepted:** 17 January 2014

Article published online: 4 April 2014

New Microbe New Infect 2014; **2**: 58–63

Corresponding author: A. Galiana, Dpto Microbiología, Hospital Maciel, UDYCI, Montevideo, Uruguay.
E-mail: galiana@netgate.com.uy

Introduction

Carbapenems are recommended for severe infections caused by extended spectrum β -lactamase (ESBL) -producing Enterobacteria, because of their resistance to third-generation cephalosporins and associated resistance to almost all other antibiotics. Therefore the emergence of carbapenem-resistance in Enterobacteria is worrying, and could be related to several combined mechanisms involving outer membrane

permeability defects, hyperproduction of AmpC cephalosporinases, ESBL and carbapenemase production [1].

Klebsiella pneumoniae carbapenemases (KPC) are the most frequent carbapenemases found in *Klebsiella pneumoniae* and are mostly plasmid encoded, but chromosomal location has also been reported [2]. As the gene encoding KPC usually resides on transferable plasmids, it is capable of disseminating to other Gram-negative genera [3]. The worldwide spread of KPC-producing *K. pneumoniae* strains (KPC-KP) has revealed the successful dissemination of a major clone defined as sequence type 258 (ST258). Since 2006, KPC-KP has arisen in South America, particularly in countries bordering Uruguay—Argentina and Brazil [4,5].

A high frequency of ESBL-producing *K. pneumoniae* isolates (70%) has been reported in intensive care unit (ICU) patients but no cases of KPC-producing isolates had been reported in

the country up to April 2011 [6]. We describe the first two clinical cases of KPC-KP infections in Uruguay, their phenotypic and genotypic characteristics, the shift of resistance patterns during antibiotic treatment and the infection control measures adopted.

Methods

Hospital setting characteristics

The 'Sanatorio Mautone' is a 65-bed acute general hospital located in Maldonado-Punta del Este, a tourist area receiving 500 000 tourists annually from Argentina, Brazil and to a lesser extent from the USA and Europe. The ICU has six beds, one in an isolation room and the others in a common area separated by curtains.

Clinical cases

Patient A. On 20 February 2011 a 30-year-old man (Table 1) was admitted from home to the ICU for severe enteric sepsis caused by a *Salmonella* sp. that was nalidixic acid and ciprofloxacin susceptible, recovered from blood and stool cultures. He was mechanically ventilated due to septic shock and acute respiratory distress syndrome and intravenous ciprofloxacin treatment was started. This patient had Evans syndrome associated with systemic lupus erythematosus treated with corticosteroids and immunosuppressants. He had never required medical care in any other country. He first developed an *Escherichia coli* tracheobronchitis treated with piperacillin-tazobactam, and later developed a *Pseudomonas aeruginosa* ventilator-associated pneumonia with secondary bacteraemia that was treated with imipenem for 13 days. On

26 March a urine specimen grew *P. aeruginosa* and KPC-KP (A1). A second urine specimen grew KPC-KP (A2) as well. This catheter-related asymptomatic bacteriuria was not treated. On 31 March the patient developed fever and septic shock and blood cultures grew *Salmonella* sp. susceptible to nalidixic acid, ciprofloxacin and imipenem, treated with ciprofloxacin and imipenem; he progressed to refractory septic shock and died on 7 April. On 6 April the central venous catheter tip grew 10 CFU of KPC-KP (A3) and the blood cultures were negative.

Patient B. On 15 March 2011 a 67-year-old man (Table 1) with severe chest trauma was hospitalized in ICU with respiratory failure requiring mechanical ventilation. Piperacillin-tazobactam treatment was started for suspected pulmonary infection. The patient was diabetic with a history of chronic hypertension. He had not required medical care in any other country. On 20 March the patient developed a *P. aeruginosa* ventilator-associated pneumonia with secondary bacteraemia treated with imipenem for 9 days and then with piperacillin-tazobactam and ciprofloxacin. Patient condition improved and the orotracheal tube was removed on 4 April. Three days later he developed respiratory failure and mechanical ventilation was reinstalled. On 7 April KPC-KP (B1) was recovered from respiratory secretions and from the central venous catheter tip (100 CFU) (B2). On 9 April the patient developed a ventilator-associated pneumonia caused by KPC-KP (B3) with septic shock. Blood cultures were negative, and cultures from urine and perianal swabs grew KPC-KP (B4, B5). Initially a high dose of doxycycline (200 mg every 6 h) plus rifampicin (600 mg every 24 h) and meropenem (2 g in a 3-h infusion every 8 h) were started. The patient's condition improved and noradrenalin infusion was

TABLE 1. Characteristics of the patients, treatments and KPC-producing *Klebsiella pneumoniae* isolates

	Diagnosis and antimicrobial treatment	Date	Isolate (Specimen)	Synergy tests/ <i>bla</i> _{KPC-2}	Sequence type	PFGE (XbaI)
Patient A	SLE, Enteric <i>Salmonella</i> sepsis; CIP	20/02				
	<i>Escherichia coli</i> Tracheobronchitis; PTZ	27/02				
	<i>Pseudomonas aeruginosa</i> VAP with secondary bacteraemia; IMP	10 al 23/03				
	<i>P. aeruginosa</i> persistent tracheal	26/03	A1 (Urine)	+/nd	nd	nd
	<i>Samonella</i> bacteraemia and Septic shock; IMP plus CIP	30/03	A2 (Urine)	+/+	ST258	A
		31/03				
Patient B		06/04	A3 (Catheter)	+/nd	nd	nd
	Chest trauma, respiratory failure, Diabetic; PTZ	15/03				
	<i>P. aeruginosa</i> VAP with secondary bacteraemia; IMP	20 al 30/03				
	<i>P. aeruginosa</i> persistent tracheal infection	1 al 09/04				
	Mechanical ventilation reinstalled	07/04	B1 (TA)	+/+	ST258	A
			B2 (Catheter)	+/+	nd	A
			B3 (TA)	+/nd	nd	nd
			B4 (Urine)	+/nd	nd	nd
			B5 (Rectal)	+/nd	nd	nd
			B6 (TA)	+/+	ST258	A
	TIG plus RIF plus MEM Respiratory failure, <i>P. aeruginosa</i> bacteraemia	14/04 28/04				

CIP, ciprofloxacin; PFGE, pulsed-field gel electrophoresis; PTZ, piperacillin-tazobactam; IMP, imipenem; DOX, doxycycline; RIF, rifampin; MEM, meropenem; TYG, tigecycline; A₁, >10⁵ CFU/mL *K. pneumoniae* and *P. aeruginosa*; A₂, >10⁵ CFU/mL of *K. pneumoniae*; A₃, 10 CFU of *K. pneumoniae* in the tip of central line catheter; B₂, 100 CFU of *K. pneumoniae*; B₄, >10⁵ CFU mL⁻¹ of *K. pneumoniae*; +, difference of ≥5 mm in zones between MEM and MEM plus boronic acid and <5 mm in zone between MEM and MEM plus cloxacillin and MEM plus dipicolinic acid; nd, not determined; SLE, systemic lupus erythematosus; VAP, ventilator-associated pneumonia; TA, tracheal aspirate.

stopped. On 14 April doxycycline was substituted by tigecycline (100 mg every 12 h), which became available for the first time in Uruguay. Antimicrobial treatment was stopped on 25 April. On 28 April the respiratory failure persisted, respiratory secretions were positive for KPC-KP (B6) and *P. aeruginosa* and blood culture was positive for *P. aeruginosa*. Finally on 3 May the patient died of refractory respiratory failure.

Infection prevention and control measures

The Infection Control Committee, considering the unusual antimicrobial resistance phenotype of *K. pneumoniae* isolates suspected nosocomial cross-transmission and decided to implement control measures, perform an epidemiological investigation and notify the public health authorities [7,8]. Control measures adopted were: meeting with hospital (clinicians, nurses, laboratory, housekeeping) and administration staff; extended contact isolation precautions for ICU patients with daily monitoring (isolation room and dedicated staff for the colonized and the infected patients, exclusive work clothes to use with these patients, strict hand hygiene with alcohol gel, reinforcement of the unshared use of instruments and disinfection between patients of shared instruments); screening of patients in contact with colonized or infected patients and pre-emptive isolation while awaiting results; closing the ICU to new patients; and reinforcement of environmental hygiene with alcohol or chlorinated agents. The surveillance cultures for the identification of KPC-KP intestinal-tract-colonized patients were performed according to the CDC protocol [9]. Respiratory secretions and urine were evaluated following conventional culture methods.

Identification and antimicrobial susceptibility studies

The identification and the antibiotic susceptibility testing were performed using the VITEK 2 C (bioMérieux, Marcy l'Etoile, France) system. The MICs of imipenem, meropenem, tigecycline, colistin and gentamycin were determined using *E*-test (bioMérieux). CLSI clinical breakpoints were applied, except for tigecycline and colistin where EUCAST (<http://www.eucast.org>) breakpoints were used [10,11]. ESBL testing was performed according to CLSI guidelines.

Susceptibility to fosfomycin was assayed by disc diffusion [12]. KPC phenotype was determined by synergy test using KPC/MBL confirm kit (ROSCO Diagnostica A/S, Denmark). The population analysis profile was determined for meropenem as described elsewhere [13].

Molecular studies

Screening for resistance genes was performed by PCR, following reported conditions for *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M},

*bla*_{KPC}, *bla*_{IMP}, *bla*_{VIM} gene families, and *bla*_{PER-2}, *aacA4*, *qnrA* and *qnrB* genes [14–20].

The genetic environment of *bla*_{KPC-2} gene was studied by PCR mapping with specific primers for ISKpn6 or ISKpn7 or *tnpA* and *bla*_{KPC-2}. PCR amplification of the complete *ompK36* gene was performed [21].

Crude extracts were subjected to isoelectrofocusing with the use of PhastSystem and PhastaGels IEF 3–9 (Pharmacia, Stockholm, Sweden).

Genetic relatedness

The genetic relatedness of KPC-KP isolates was evaluated by pulsed field gel electrophoresis using *Xba*I-digested total DNA and interpreted by Tenover criteria [22]. Multilocus sequence typing with seven housekeeping genes was performed according to the protocol described on the *K. pneumoniae* multilocus sequence typing website (<http://www.pasteur.fr/mlst/Kpneumoniae.html>).

Mating experiments

To determine whether the *bla*_{KPC-2} gene was on a transferable element, isolates AI and BI—cefotaxime resistant, rifampin and sodium azide sensitive—were mated in three independent assays with *E. coli* strain Top10—cefotaxime susceptible, rifampin and sodium azide resistant. They were cultured for 18 h at 35°C, in Müller–Hinton agar (MHA) containing cefotaxime 2 mg/L or rifampin 200 mg/L. The growth was suspended in MH broth (MHB) to achieve a 1 MacFarland turbidity standard, and 0.5 mL of the mix of equal volumes of the donor and receptor suspensions was plated as a drop in the middle of an MHA plate, and incubated for 18 h at 35°C. Serial decimal dilutions of the suspension in 1 mL MHB of the total growth were prepared. Transconjugants were selected from 10⁻¹ and 10⁻² dilutions in MHA containing cefotaxime 2 mg/L and rifampin 200 mg/L and confirmed by positive growth in MHA containing sodium azide 100 µg/mL and positive PCR for *bla*_{KPC-2} gene.

Results

The ICU remained closed to new admissions while KPC-KP-infected patients were still hospitalized. Three patients were considered contacts because they shared their stay in ICU with KPC-KP-infected patients. Two of them were discharged with negative surveillance cultures that persisted negative on days 15 and 30 thereafter. Surveillance cultures of the third contact were performed every 48 h with negative results. The epidemiological investigation identified a diabetic patient with a history of contact with the healthcare system in New York,

USA, who was admitted to the ICU 17 days before the first isolation of KPC-KP. She had a severe urosepsis caused by non-multiresistant *E. coli* and had multiple episodes of diarrhoea during the 5 days of hospitalization. When the ICU was free of patients, it underwent a thorough cleaning and environmental disinfection. Five months later two colonized cases were detected (asymptomatic urinary catheter bacteriuria and hepatic drain of quistostomy), similar control measures were applied, surveillance cultures were performed during the next 6 months and no more cases have been identified since then.

All *K. pneumoniae* isolates recovered showed a multiresistant phenotype but were susceptible to fosfomycin, ESBL-negative and exhibited a KPC phenotype. Different values for MICs to β -lactams and gentamycin were observed for the isolates from patient B (Table 2). The fosfomycin inhibition zone diameters were 22 and 17 mm for B1 and B6 isolates, respectively. Scattered colonies were observed within the inhibition zone of meropenem for A2 and B1 whereas B6 showed no inhibition zone.

The B1 isolate population analysis profile showed a heterogeneous population with a subset of 0.01–0.001% growing at meropenem concentrations ranging from 16 to 128 $\mu\text{g/mL}$. The B6 isolate population analysis profile showed that >0.01% of cells grew up to 512 $\mu\text{g/mL}$.

The isolates A2, B1, B2 and B6 revealed the presence of a *bla*_{KPC-2}, *bla*_{TEM-1}, *bla*_{SHV-1} and *aacA4* genes. Isoelectrofocusing showed that these isolates shared two common β -lactamase activities with isoelectric points of 5.4 and 6.7, characteristic of TEM-1 and KPC-2 enzymes, respectively. PCR mapping revealed a 4-kb genetic region containing *tnpA*, *ISKpn7*, *bla*_{KPC-2} and *ISKpn6* genes, consistent with a Tn3-based Tn4401 isoform a, since a 100-bp deletion was detected upstream of the *bla*_{KPC-2} gene (Fig. 1) [23]. Sequence analysis of *ompK36* DNA revealed a 99% similarity with a described gene encoding a functional OmpK36 porin (Accession number FJ577673).

Biparental conjugation did not render transconjugants, indicating a conjugation frequency less than 1×10^{-8} /recipient.

Discussion

In the present study we describe the first nosocomial outbreak caused by KPC-KP in Uruguay. Considering that none of the patients had a history of recent travel abroad, it is possible that an unrecognized colonized patient with a history of admission in a healthcare facility in one of the endemic areas introduced

TABLE 2. Susceptibility of KPC-producing *Klebsiella pneumoniae* isolates

<i>K. pneumoniae</i> isolate	Vitek MIC $\mu\text{g mL}^{-1}$ to:											E-test MIC $\mu\text{g mL}^{-1}$ to:			
	TZP	FOX	CTX	CAZ	CEP	GEM	ANK	CIP	COL	IPM	MEM	IPM	MEM	TYG	COL
A1	$\geq 128/4$	≥ 64	16	16	8	≥ 16	16	≥ 4	≥ 16	8	4	8	4	2	24
A2	$\geq 128/4$	≥ 64	16	16	8	≥ 16	16	≥ 4	≥ 16	8	4	8	4	2	24
B1	$\geq 128/4$	≥ 64	16	16	8	$\geq 16^a$	32	≥ 4	≥ 16	≥ 16	4	8	8	2	24
B2	$\geq 128/4$	≥ 64	16	16	8	≥ 16	32	≥ 4	≥ 16	≥ 16	4	8	8	2	24
B3	$\geq 128/4$	≥ 64	16	16	8	≥ 16	32	≥ 4	≥ 16	≥ 16	4	8	8	2	24
B5	$\geq 128/4$	≥ 64	16	32	8	≥ 16	32	≥ 4	≥ 16	≥ 16	8	16	8	2	24
B6	$\geq 128/4$	≥ 64	≥ 64	≥ 64	≥ 64	$\geq 16^b$	≥ 64	≥ 4	≥ 16	≥ 16	≥ 16	≥ 32	$\geq 32^c$	2	24

PTZ, piperacillin-tazobactam; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CEP, cefepime; GEM, gentamicin; ANK, amikacin; CIP, ciprofloxacin; COL, colistin; IPM, imipenem; MEM, meropenem; TYG, tigecycline.

^aE-test MIC 36 $\mu\text{g/mL}$.

^bE-test MIC 96 $\mu\text{g/mL}$.

^cE-test MIC 256 $\mu\text{g/mL}$.




FIG. 1. Schematic representation of the genetic structures from Tn4401 isoform a identified in the surroundings of *bla*_{KPC-2} gene. Genes and their corresponding transcription orientations are shown by horizontal arrows. Empty triangles represent inverted repeats (IRs) that flank Tn4401 structure. Internal grey triangles represent IRs from *ISKpn6* and *ISKpn7*. The 100-bp deletion characteristic of Tn4401 isoform a is indicated above the sequence. Primers used are shown below the sequence: KPCfw, KPCrv [15], 816U, 3098U, 4714 [26].

the causative agent to our hospital, as may be the case identified in the root-cause analysis [24].

The KPC-KP isolates exhibited a multiresistant antibiotic phenotype including resistance to colistin and intermediate susceptibility to tigecycline. Based on pulsed field gel electrophoresis analysis they represent a single clone and they belong to the internationally distributed ST258 KPC-KP clone, allowing us to propose their introduction and the occurrence of cross-transmission between patients. Both clinical cases had risk factors previously reported to be associated with the acquisition of KPC-producing bacteria: prolonged ICU stay, invasive devices, immunosuppression and previous multiple antibiotic therapies, including ciprofloxacin, tazobactam-piperacillin and imipenem [25].

This is the first description of isolates belonging to the KPC-KP ST258, exhibiting co-resistance to gentamycin, colistin and tigecycline intermediate susceptibility, acquiring further amikacin resistance.

The first patient had a KPC-KP asymptomatic catheter-related bacteriuria, considered the source for the cross-transmission, and his death was related to *Salmonella* sepsis. In contrast, the second patient had multiple sites colonized, and developed severe sepsis associated with KPC-KP ventilator-associated pneumonia.

The core measures adopted according to European expert opinion were reinforced and have been successful in preventing evolution towards resistance dissemination [8].

The deletions in the upstream genetic environment of the *bla_{KPC}* gene increased the level of KPC production, in accordance with the high-level of carbapenem resistance observed [26]. Even though B1 and B6 isolates were the same strain based on pulsed field gel electrophoresis analysis, they had different behaviours concerning their antibiotic susceptibility and the population analysis profile study. A progressive increase in the MICs for aminoglycosides and β -lactams, and a decreased susceptibility to fosfomycin was observed throughout the administration of combined antimicrobial regimens in patient B. Even though pre- and post-treatment isolates possessed *ompk36* genes identical to a previously described functional protein, a decrease in the *ompk36* expression level could not be discounted.

In addition, selection of mutants with resistance to different antibiotic classes could have emerged by the acquisition of a resistance mechanism with a broad range specificity spectrum. Further studies are needed to understand the molecular basis of these complex and variable resistance phenotypes and to evaluate their frequency and clinical significance. To counteract the emergency of carbapenem resistance, new antibiotic regimens need to be developed and hospital infection control and diagnostic microbiology practice must be improved.

Conflict of Interest

None declared.

References

- Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. *Korean J Intern Med* 2012; 27: 128–142.
- Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP; Colombian Nosocomial Resistance Study Group. First identification of *Pseudomonas aeruginosa* isolates producing a KPC-type carbapenem-hydrolyzing β -lactamase. *Antimicrob Agents Chemother* 2007; 51: 1553–1555.
- Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of *Enterobacteriaceae* isolated in the United States Medical Centers: report from the MYSTIC Program (1999–2005). *Diagn Microbiol Infect Dis* 2006; 56: 367–372.
- Gomez SA, Pasteran FG, Faccone D et al. Clonal dissemination of *Klebsiella pneumoniae* ST258 harbouring KPC-2 in Argentina. *Clin Microbiol Infect* 2011; 17: 1520–1524.
- Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2-producing *Klebsiella pneumoniae* in Brazil. *Antimicrob Agents Chemother* 2009; 53: 333–334.
- Guerra SE, Albornoz H, Rosa R et al. Incidences of nosocomial infections in Uruguayan adult intensive care units 2010. International Conference on Prevention & Infection Control (ICPIC 2011), Geneva, Switzerland, 29 June–2 July 2011. *BMC Proc* 2011; 5(suppl 6): 77.
- Centers for Diseases Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase producing *Enterobacteriaceae* in acute care facilities. *MMWR Morb Mortal Wkly Rep* 2009; 58: 256–260.
- Carmeli Y, Akova M, Cornaglia G et al. Controlling the spread of carbapenemase-producing gram-negatives: therapeutic approach and infection control. *Clin Microbiol Infect* 2010; 16: 102–111.
- CDC. Laboratory protocol for detection of carbapenem-resistant or carbapenemase-producing, *Klebsiella* spp. and *E. coli* from rectal swabs. Atlanta, GA: US Department of Health and Human Services, CDC, 2009.
- Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing; 21st Informational Supplement*. CLSI Document M100-S21. Wayne, PA: CLSI, 2011.
- Clinical and Laboratory Standards Institute. *Methods of dilution antimicrobial susceptibility test for bacteria that grow aerobically; Approved Standard 8th ed*. CLSI Document M7-A8. Wayne, PA: CLSI, 2009.
- Pasteran F, Lucero C, Rapoport M et al. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for *Enterobacteriaceae*. *J Infect Dev Ctries* 2012; 6: 452–456.
- Pournaras S, Kristo I, Vrioni G et al. Characteristics of meropenem heteroresistance in *Klebsiella pneumoniae* carbapenemase (KPC)-producing clinical isolates of *K. pneumoniae*. *J Clin Microbiol* 2010; 48: 2601–2604.
- Ma L, Chang FY, Fung CP et al. Variety of TEM-, SHV-, and CTX-M-type β -lactamases present in recent clinical isolates of *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter cloacae* from Taiwan. *Microb Drug Resist* 2005; 11: 31–39.
- Chowdhury PR, Ingold A, Vanegas N et al. Dissemination of multiple drug resistance genes by Class I integrons in *Klebsiella* isolates from four countries: a comparative study. *Antimicrob Agents Chemother* 2011; 55: 3140–3149.

16. Endimiani A, Carias LL, Hujer AM et al. Presence of plasmid-mediated quinolone resistance in *Klebsiella pneumoniae* isolates possessing *bla_{KPC}* in the United States. *Antimicrob Agents Chemother* 2008; 52: 2680–2682.
17. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase producing *Enterobacteriaceae*. *Emerg Infect Dis* 2011; 17: 1791–1798.
18. Power P, Di Conza J, Rodríguez MM et al. Biochemical characterization of PER-2 and genetic environment of *bla_{PER-2}*. *Antimicrob Agents Chemother* 2007; 51: 2359–2365.
19. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of *aac(6′)-Ib-cr* encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* 2006; 50: 3953–3955.
20. Toleman MA, Bennett PM, Walsh TR. Common regions e.g. *orf513* and antibiotic resistance: IS91-like elements evolving complex class I integrons. *J Antimicrob Chemother* 2006; 58: 1–6.
21. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* to Upstate New York. *Clin Infect Dis* 2006; 43: 26–28.
22. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* 1995; 33: 2233–2239.
23. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisitions of the β-lactamase *bla_{KPC}* gene. *Antimicrob Agents Chemother* 2008; 52: 1257–1263.
24. Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. *Clin Infect Dis* 2011; 53: 49–56.
25. Nordmann P, Cuzon G, Nass T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet Infect Dis* 2009; 9: 228–236.
26. Kitchel B, Rasheed JK, Endimiani A, et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2010; 54: 4201–4207.